Drug Profile
Research programme: PFKFB3 inhibitors - Advanced Cancer Therapeutics
Alternative Names: 3PO; PFKFB3 inhibitors - Advanced Cancer TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Louisville
- Developer Advanced Cancer Therapeutics
- Class Small molecules
- Mechanism of Action PFKFB3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Glioblastoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 11 Oct 2012 Advanced Cancer Therapeutics receives SBIR grant from the National Cancer Institute for development of a PFKFB3 inhibitor in Glioblastoma